Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April–June 2022
Irina Kislaya(German Center for Infection Research), João Almeida Santos(National Institute of Health Dr. Ricardo Jorge), Sara Ramalhete(National Institute of Health Dr. Ricardo Jorge), Ana Paula Rodrigues(Microsoft (Brazil)), Aryse Melo(National Institute of Health Dr. Ricardo Jorge), Marta Barreto(Administração Regional de Saúde de Lisboa e Vale do Tejo), Sofia Soeiro(National Institute of Health Dr. Ricardo Jorge), Camila Henriques(National Institute of Health Dr. Ricardo Jorge), Carla Manita(National Institute of Health Dr. Ricardo Jorge), Carlos Aniceto(National Institute of Health Dr. Ricardo Jorge)
Cited by 9
Related Papers
Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020
|Eurosurveillance|2020|238
The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century
|PLoS ONE|2019|185
European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?
|Clinical Microbiology and Infection|2019|140
Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries
|Influenza and Other Respiratory Viruses|2021|128
Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017
|Eurosurveillance|2017|125